Leonardo Punzi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6632118/publications.pdf

Version: 2024-02-01

241 papers 10,619 citations

60 h-index 88 g-index

253 all docs

253 docs citations

times ranked

253

11763 citing authors

#	Article	IF	CITATIONS
1	Identification of a central role for complement in osteoarthritis. Nature Medicine, 2011, 17, 1674-1679.	15.2	470
2	CCL2/CCR2, but not CCL5/CCR5, mediates monocyte recruitment, inflammation and cartilage destruction in osteoarthritis. Annals of the Rheumatic Diseases, 2017, 76, 914-922.	0.5	277
3	Gout: why is this curable disease so seldom cured?. Annals of the Rheumatic Diseases, 2012, 71, 1765-1770.	0.5	228
4	2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Annals of the Rheumatic Diseases, 2020, 79, 31-38.	0.5	225
5	Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Annals of the Rheumatic Diseases, 2015, 74, 2117-2122.	0.5	181
6	Improving cardiovascular and renal outcomes in gout: what should we target?. Nature Reviews Rheumatology, 2014, 10, 654-661.	3.5	169
7	Overlap connective tissue disease syndromes. Autoimmunity Reviews, 2013, 12, 363-373.	2.5	150
8	The clinical features, diagnosis and classification of dermatomyositis. Journal of Autoimmunity, 2014, 48-49, 122-127.	3.0	148
9	Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmunity Reviews, 2012, 12, 225-229.	2.5	146
10	Post-traumatic arthritis: overview on pathogenic mechanisms and role of inflammation. RMD Open, 2016, 2, e000279.	1.8	145
11	Calprotectin in rheumatic diseases. Experimental Biology and Medicine, 2017, 242, 859-873.	1.1	131
12	Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. Annals of the Rheumatic Diseases, 2018, 77, 104-110.	0.5	131
13	Blau syndrome, clinical and genetic aspects. Autoimmunity Reviews, 2012, 12, 44-51.	2.5	126
14	Antiâ€inflammatory effects of polyphenols in arthritis. Journal of the Science of Food and Agriculture, 2018, 98, 1653-1659.	1.7	124
15	Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis and Rheumatism, 1993, 36, 485-489.	6.7	122
16	Resistant Behçet Disease Responsive to Anakinra. Annals of Internal Medicine, 2008, 149, 284.	2.0	122
17	Galectin-3 in autoimmunity and autoimmune diseases. Experimental Biology and Medicine, 2015, 240, 1019-1028.	1.1	120
18	Autoantibodies in Polymyositis and Dermatomyositis. Current Rheumatology Reports, 2013, 15, 335.	2.1	114

#	Article	IF	Citations
19	Emerging and critical issues in the pathogenesis of lupus. Autoimmunity Reviews, 2013, 12, 523-536.	2.5	114
20	Anakinra treatment in drug-resistant Behcet's disease: a case series. Clinical Rheumatology, 2015, 34, 1293-1301.	1.0	114
21	Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases, 2018, 77, 1757-1764.	0.5	113
22	Optimizing outcome in SLE: treating-to-target and definition of treatment goals. Autoimmunity Reviews, 2014, 13, 770-777.	2.5	108
23	Erosive osteoarthritis. Best Practice and Research in Clinical Rheumatology, 2004, 18, 739-758.	1.4	107
24	Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus. Arthritis Care and Research, 2017, 69, 115-123.	1.5	107
25	Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn's disease. RMD Open, 2015, 1, e000097.	1.8	103
26	Rehabilitation Treatment in Patients with Ankylosing Spondylitis Stabilized with Tumor Necrosis Factor Inhibitor Therapy. A Randomized Controlled Trial. Journal of Rheumatology, 2011, 38, 1335-1342.	1.0	98
27	Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clinical Rheumatology, 2014, 33, 833-839.	1.0	98
28	Pregnancy, cytokines, and disease activity in systemic lupus erythematosus. Arthritis and Rheumatism, 2004, 51, 989-995.	6.7	95
29	Serpins, Immunity and Autoimmunity: Old Molecules, New Functions. Clinical Reviews in Allergy and Immunology, 2013, 45, 267-280.	2.9	94
30	Anti-SAE antibodies in autoimmune myositis: Identification by unlabelled protein immunoprecipitation in an Italian patient cohort. Journal of Immunological Methods, 2012, 384, 128-134.	0.6	90
31	Commentary on recent therapeutic guidelines for osteoarthritis. Seminars in Arthritis and Rheumatism, 2015, 44, 611-617.	1.6	88
32	Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis. Autoimmunity Reviews, 2014, 13, 1220-1229.	2.5	86
33	Chronic autoimmune thyroiditis and rheumatic manifestations. Joint Bone Spine, 2004, 71, 275-283.	0.8	85
34	Predictors of maternal and fetal complications in SLE patients: a prospective study. Immunologic Research, 2014, 60, 170-176.	1.3	84
35	Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. Clinical Rheumatology, 2016, 35, 1683-1689.	1.0	83
36	The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients. Annals of the Rheumatic Diseases, 2017, 76, 562-565.	0.5	83

#	Article	IF	Citations
37	Pregnancy and vasculitis: A systematic review of the literature. Autoimmunity Reviews, 2012, 11, A447-A459.	2.5	81
38	Effects of an educational–behavioral joint protection program on people with moderate to severe rheumatoid arthritis: a randomized controlled trial. Clinical Rheumatology, 2007, 26, 2043-2050.	1.0	79
39	Anti-dsDNA Antibody Isotypes in Systemic Lupus Erythematosus: IgA in Addition to IgG Anti-dsDNA Help to Identify Glomerulonephritis and Active Disease. PLoS ONE, 2013, 8, e71458.	1.1	79
40	Clinical and laboratory manifestations of elderly onset psoriatic arthritis: a comparison with younger onset disease. Annals of the Rheumatic Diseases, 1999, 58, 226-229.	0.5	77
41	Diagnosis and classification of relapsing polychondritis. Journal of Autoimmunity, 2014, 48-49, 53-59.	3.0	77
42	Cytokine levels in human synovial fluid during the different stages of acute gout: role of transforming growth factor \hat{l}^21 in the resolution phase. Annals of the Rheumatic Diseases, 2012, 71, 621-624.	0.5	74
43	lgE-mediated mast cell activation promotes inflammation and cartilage destruction in osteoarthritis. ELife, 2019, 8, .	2.8	74
44	A new CARD15 mutation in Blau syndrome. European Journal of Human Genetics, 2005, 13, 742-747.	1.4	72
45	Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: results from the KING observational study of the Italian Society for Rheumatology (SIR). Arthritis Research and Therapy, 2013, 15, R101.	1.6	72
46	A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. Frontiers in Pharmacology, 2016, 7, 380.	1.6	72
47	The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: Clinical manifestations and long-term follow-up. Seminars in Arthritis and Rheumatism, 2014, 43, 818-823.	1.6	71
48	Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunologic Research, 2015, 61, 147-153.	1.3	70
49	Gout as autoinflammatory disease: New mechanisms for more appropriated treatment targets. Autoimmunity Reviews, 2012, 12, 66-71.	2.5	68
50	Biological Treatments in Behçet's Disease: Beyond Anti-TNF Therapy. Mediators of Inflammation, 2014, 2014, 1-14.	1.4	68
51	Distribution of HLA-B27 subtypes in Sardinia and continental Italy and their association with spondylarthropathies. Arthritis and Rheumatism, 2005, 52, 3319-3321.	6.7	67
52	Monogenic Autoinflammatory Syndromes: State of the Art on Genetic, Clinical, and Therapeutic Issues. International Journal of Rheumatology, 2013, 2013, 1-15.	0.9	67
53	The Sex Influence on Response to Tumor Necrosis Factor-α Inhibitors and Remission in Axial Spondyloarthritis. Journal of Rheumatology, 2018, 45, 195-201.	1.0	66
54	JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunologic Research, 2014, 58, 61-69.	1.3	65

#	Article	IF	Citations
55	Biological Treatments: New Weapons in the Management of Monogenic Autoinflammatory Disorders. Mediators of Inflammation, 2013, 2013, 1-16.	1.4	64
56	Long-term safety of anti-TNF- $\hat{l}\pm$ in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clinical Rheumatology, 2014, 33, 273-276.	1.0	64
57	Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. Clinical Rheumatology, 2018, 37, 2233-2240.	1.0	64
58	Co-stimulatory modulation in rheumatoid arthritis: The role of (CTLA4-Ig) abatacept. Autoimmunity Reviews, 2008, 8, 76-82.	2.5	63
59	Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-α blockade in the knee joint. Arthritis Research and Therapy, 2010, 12, R148.	1.6	62
60	Prognosis of scleroderma renal crisis: a long-term observational study. Nephrology Dialysis Transplantation, 2012, 27, 4398-4403.	0.4	61
61	Influence of tumor necrosis factor \hat{l}_{\pm} inhibitors on testicular function and semen in spondyloarthritis patients. Fertility and Sterility, 2014, 101, 359-365.	0.5	61
62	Remission in ankylosing spondylitis treated with anti-TNF-Â drugs: a national multicentre study. Rheumatology, 2013, 52, 1914-1919.	0.9	60
63	Inflammatory osteoarthritis of the hand. Best Practice and Research in Clinical Rheumatology, 2010, 24, 301-312.	1.4	59
64	The effects of combined spa therapy and rehabilitation on patients with ankylosing spondylitis being treated with TNF inhibitors. Rheumatology International, 2013, 33, 241-245.	1.5	58
65	Clinical and genetic aspects of Blau syndrome: A 25-year follow-up of one family and a literature review. Autoimmunity Reviews, 2009, 8, 228-232.	2.5	56
66	Elderly onset of primary Sjögren's syndrome: Clinical manifestations, serological features and oral/ocular diagnostic tests. Comparison with adult and young onset of the disease in a cohort of 336Âltalian patients. Joint Bone Spine, 2011, 78, 171-174.	0.8	56
67	A Brief History of IL-1 and IL-1 Ra in Rheumatology. Frontiers in Pharmacology, 2017, 8, 293.	1.6	56
68	Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. Clinical and Experimental Rheumatology, 2012, 30, 856-63.	0.4	56
69	High-density lipoproteins downregulate CCL2 production in human fibroblast-like synoviocytes stimulated by urate crystals. Arthritis Research and Therapy, 2010, 12, R23.	1.6	54
70	Treatment of 139 Pregnancies in Antiphospholipid-positive Women Not Fulfilling Criteria for Antiphospholipid Syndrome: A Retrospective Study. Journal of Rheumatology, 2013, 40, 425-429.	1.0	54
71	Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey. Arthritis Research and Therapy, 2016, 18, 78.	1.6	52
72	Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology. Clinical and Experimental Rheumatology, 2011, 29, S28-41.	0.4	52

#	Article	IF	CITATIONS
73	Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: A two-year prospective observational study. Joint Bone Spine, 2014, 81, 421-425.	0.8	51
74	Prevalence of calcium pyrophosphate and monosodium urate crystals in synovial fluid of patients with previously diagnosed joint diseases. Joint Bone Spine, 2013, 80, 287-290.	0.8	50
75	Hypomagnesemia and Chondrocalcinosis in Bartter's and Gitelman's Syndrome: Review of the Pathogenetic Mechanisms. American Journal of Nephrology, 2000, 20, 347-350.	1.4	49
76	International position paper on febuxostat. Clinical Rheumatology, 2010, 29, 835-840.	1.0	49
77	Biomechanical assessment of balance and posture in subjects with ankylosing spondylitis. Journal of NeuroEngineering and Rehabilitation, 2012, 9, 63.	2.4	49
78	Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: A case report. Joint Bone Spine, 2008, 75, 366-367.	0.8	47
79	Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature. Immunologic Research, 2013, 56, 362-370.	1.3	46
80	Clinical and pathologic considerations of the qualitative and quantitative aspects of lupus nephritogenic autoantibodies: A comprehensive review. Journal of Autoimmunity, 2016, 69, 1-11.	3.0	45
81	Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab. BMC Musculoskeletal Disorders, 2015, 16, 166.	0.8	44
82	Clinical Significance of Cytokine Determination in Synovial Fluid. Critical Reviews in Clinical Laboratory Sciences, 2002, 39, 63-88.	2.7	43
83	The Tumor Necrosis Factor-α-blocking Agent Infliximab Inhibits Interleukin 1ß (IL-1ß) and IL-6 Gene Expression in Human Osteoblastic Cells. Journal of Rheumatology, 2009, 36, 1575-1579.	1.0	43
84	The novel S59P mutation in the TNFRSF1A gene identified in an adult onset TNF receptor associated periodic syndrome (TRAPS) constitutively activates NF-κB pathway. Arthritis Research and Therapy, 2015, 17, 93.	1.6	43
85	Role of galectin-3 in autoimmune and non-autoimmune nephropathies. Autoimmunity Reviews, 2017, 16, 34-47.	2.5	43
86	Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study. Clinical Rheumatology, 2018, 37, 579-586.	1.0	43
87	Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis. Journal of Autoimmunity, 2016, 74, 94-105.	3.0	42
88	New Biochemical Insights into the Pathogenesis of Osteoarthritis and the Role of Laboratory Investigations in Clinical Assessment. Critical Reviews in Clinical Laboratory Sciences, 2005, 42, 279-309.	2.7	41
89	A combination therapy protocol of plasmapheresis, intravenous immunoglobulins and betamethasone to treat anti-Ro/La-related congenital atrioventricular block. A case series and review of the literature. Autoimmunity Reviews, 2013, 12, 768-773.	2.5	41
90	Work productivity is associated with disease activity and functional ability in Italian patients with early axial spondyloarthritis: an observational study from the SPACE cohort. Arthritis Research and Therapy, 2016, 18, 265.	1.6	41

#	Article	IF	Citations
91	How the Mediterranean diet and some of its components modulate inflammatory pathways in arthritis. Swiss Medical Weekly, 2015, 145, w14190.	0.8	41
92	Fibromyalgia in Italian patients with primary Sjögren's syndrome. Joint Bone Spine, 2002, 69, 51-57.	0.8	40
93	Mud-bath treatment in spondylitis associated with inflammatory bowel disease – a pilot randomised clinical trial. Joint Bone Spine, 2007, 74, 436-439.	0.8	39
94	Adult-onset Still's disease with myocarditis successfully treated with the interleukin-1 receptor antagonist anakinra. Joint Bone Spine, 2011, 78, 100-101.	0.8	39
95	Effects of mud-bath therapy in psoriatic arthritis patients treated with TNF inhibitors. Clinical evaluation and assessment of synovial inflammation by contrast-enhanced ultrasound (CEUS). Joint Bone Spine, 2015, 82, 104-108.	0.8	38
96	Mediterranean diet and knee osteoarthritis outcomes: A longitudinal cohort study. Clinical Nutrition, 2019, 38, 2735-2739.	2.3	38
97	Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis. Autoimmunity Reviews, 2007, 6, 524-528.	2.5	37
98	Arthrocentesis and Synovial Fluid Analysis in Clinical Practice. Annals of the New York Academy of Sciences, 2009, 1154, 152-158.	1.8	37
99	Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study. Rheumatology, 2010, 49, 1107-1111.	0.9	37
100	The impact of knee and hip chondrocalcinosis on disability in older people: the ProVA Study from northeastern Italy. Annals of the Rheumatic Diseases, 2011, 70, 1937-1943.	0.5	37
101	Refractory pemphigus foliaceus and Behçet's disease successfully treated with tocilizumab. Immunologic Research, 2013, 56, 390-397.	1.3	37
102	Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome. Thrombosis and Haemostasis, 2013, 109, 901-908.	1.8	37
103	High reactive oxygen species in fibrotic and nonfibrotic skin of patients with diffuse cutaneous systemic sclerosis. Free Radical Biology and Medicine, 2015, 87, 282-289.	1.3	37
104	Remission in Nonradiographic Axial Spondyloarthritis Treated with Anti-tumor Necrosis Factor-α Drugs: An Italian Multicenter Study. Journal of Rheumatology, 2015, 42, 258-263.	1.0	37
105	Vascular perfusion kinetics by contrast-enhanced ultrasound are related to synovial microvascularity in the joints of psoriatic arthritis. Clinical Rheumatology, 2015, 34, 1903-1912.	1.0	36
106	Transcriptional network profile on synovial fluid T cells in psoriatic arthritis. Clinical Rheumatology, 2015, 34, 1571-1580.	1.0	36
107	Advances in the diagnosis and classification of systemic lupus erythematosus. Expert Review of Clinical Immunology, 2016, 12, 1309-1320.	1.3	36
108	Effectiveness and safety of ustekinumab in $na\tilde{A}$ ve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study. Clinical Rheumatology, 2018, 37, 397-405.	1.0	36

#	Article	IF	Citations
109	Balneotherapy in chronic inflammatory rheumatic diseases—a narrative review. International Journal of Biometeorology, 2018, 62, 2065-2071.	1.3	36
110	Blockade of intra-articular TNF in peripheral spondyloarthritis: Its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkers. Joint Bone Spine, 2013, 80, 165-170.	0.8	35
111	Supervised training and home-based rehabilitation in patients with stabilized ankylosing spondylitis on TNF inhibitor treatment: a controlled clinical trial with a 12-month follow-up. Clinical Rehabilitation, 2014, 28, 562-572.	1.0	34
112	YKL-40 as a Marker of Joint Involvement in Inflammatory Bowel Disease. Clinical Chemistry, 2003, 49, 1685-1688.	1.5	33
113	PTX3, Anti-PTX3, and Anti-C1q Autoantibodies in Lupus Glomerulonephritis. Clinical Reviews in Allergy and Immunology, 2015, 49, 217-226.	2.9	33
114	Plasma exchange and immunoadsorption effectively remove antiphospholipid antibodies in pregnant patients with antiphospholipid syndrome. Journal of Clinical Apheresis, 2012, 27, 200-204.	0.7	32
115	The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti- \hat{l}^2 2 glycoprotein I antibodies. A comparison with a homemade ELISA method. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1083-9.	1.4	32
116	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmunity Reviews, 2017, 16, 650-657.	2.5	32
117	The Sex Influence on Response to Tumor Necrosis Factor-α Inhibitors and Remission in Axial Spondyloarthritis. Journal of Rheumatology, 2018, 45, 195-201.	1.0	32
118	Successful use of rituximab in a young patient with immunoglobulin G4-related disease and refractory scleritis. Joint Bone Spine, 2014, 81, 190-192.	0.8	31
119	Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection. Expert Opinion on Biological Therapy, 2015, 15, 641-650.	1.4	31
120	Immunization with pentraxin 3 (PTX3) leads to anti-PTX3 antibody production and delayed lupus-like nephritis in NZB/NZW F1 mice. Journal of Autoimmunity, 2016, 74, 208-216.	3.0	30
121	Tryptophan Catabolism in Synovial Fluid of Various Arthropathies and its Relationship with Inflammatory Cytokines. Advances in Experimental Medicine and Biology, 1999, 467, 565-570.	0.8	30
122	Ex Vivo Signaling Protein Mapping in T Lymphocytes in the Psoriatic Arthritis Joints. Journal of rheumatology Supplement, The, 2015, 93, 48-52.	2.2	29
123	A recently developed MRI scoring system for hand osteoarthritis: its application in a clinical setting. Clinical Rheumatology, 2016, 35, 2079-2086.	1.0	29
124	Long-term therapy with plasma exchange in systemic sclerosis: effects on laboratory markers reflecting disease activity. Transfusion and Apheresis Science, 2001, 25, 25-31.	0.5	28
125	Blau syndrome. Best Practice and Research in Clinical Rheumatology, 2011, 25, 703-714.	1.4	28
126	High-density lipoproteins inhibit urate crystal-induced inflammation in mice. Annals of the Rheumatic Diseases, 2015, 74, 587-594.	0.5	28

#	Article	IF	CITATIONS
127	Inefficacy or Paradoxical Effect? Uveitis in Ankylosing Spondylitis Treated with Etanercept. Case Reports in Medicine, 2014, 2014, 1-4.	0.3	27
128	Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1265-70.	1.4	27
129	Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose. Clinical and Experimental Rheumatology, 2015, 33, 63-8.	0.4	27
130	Basic calcium phosphate and pyrophosphate crystals in early and late osteoarthritis: relationship with clinical indices and inflammation. Clinical Rheumatology, 2018, 37, 2847-2853.	1.0	26
131	Polydatin and Resveratrol Inhibit the Inflammatory Process Induced by Urate and Pyrophosphate Crystals in THP-1 Cells. Foods, 2019, 8, 560.	1.9	26
132	Methods used to assess remission and low disease activity in rheumatoid arthritis. Autoimmunity Reviews, 2010, 9, 161-164.	2.5	25
133	Effect of pregnancy on serum cytokines in SLE patients. Arthritis Research and Therapy, 2012, 14, R66.	1.6	25
134	Clinical and radiographic distribution of structural damage in erosive and nonerosive hand osteoarthritis. Arthritis Care and Research, 2012, 64, 1046-1053.	1.5	25
135	lgA anticardiolipin and IgA anti-Î ² 2 glycoprotein I antibody positivity determined by fluorescence enzyme immunoassay in primary antiphospholipid syndrome. Clinical Chemistry and Laboratory Medicine, 2014, 52, 1329-33.	1.4	25
136	Serological markers of erosive hand osteoarthritis. European Journal of Internal Medicine, 2013, 24, 11-15.	1.0	24
137	Serological markers in psoriatic arthritis: promising tools. Experimental Biology and Medicine, 2013, 238, 1431-1436.	1.1	24
138	Epigallocatechin-3-gallate reduces inflammation induced by calcium pyrophosphate crystals in vitro. Frontiers in Pharmacology, 2013, 4, 51.	1.6	24
139	Plasma exchange effectively removes 52†and 60â€kDa antiâ€Ro/SSA and antiâ€La/SSB antibodies in pregnant women with congenital heart block. Transfusion, 2015, 55, 1782-1786.	0.8	24
140	Development and First Validation of a Disease Activity Score for Gout. Arthritis Care and Research, 2016, 68, 1530-1537.	1.5	24
141	The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: A prospective multicentre study. Joint Bone Spine, 2016, 83, 167-171.	0.8	22
142	Serum and salivary neopterin and interferonâ€Î³ in primary Sjögren's syndromeCorrelation with clinical, laboratory and histopathologic features. Scandinavian Journal of Rheumatology, 2003, 32, 74-78.	0.6	21
143	Bartter's and Gitelman's diseases. Best Practice and Research in Clinical Rheumatology, 2011, 25, 637-648.	1.4	21
144	Cardiovascular risk factors, burden of disease and preventive strategies in patients with systemic lupus erythematosus: a literature review. Expert Opinion on Drug Safety, 2015, 14, 1373-1385.	1.0	21

#	Article	IF	CITATIONS
145	Quantitative imaging by pixel-based contrast-enhanced ultrasound reveals a linear relationship between synovial vascular perfusion and the recruitment of pathogenic IL-17A-F+IL-23+ CD161+ CD4+ T helper cells in psoriatic arthritis joints. Clinical Rheumatology, 2017, 36, 391-399.	1.0	21
146	Pro-inflammatory adipokine profile in psoriatic arthritis: results from a cross-sectional study comparing PsA subset with evident cutaneous involvement and subset "sine psoriasis― Clinical Rheumatology, 2019, 38, 2547-2552.	1.0	21
147	Working the endless puzzle of hereditary autoinflammatory disorders. Modern Rheumatology, 2014, 24, 381-389.	0.9	20
148	Pseudogout and intraarticular hyaluronate injections: Comment on the article by Disla et al. Arthritis and Rheumatism, 2000, 43, 1660-1661.	6.7	19
149	Dermatomyositis and malignancy of the pharynx in Caucasian patients: report of two observations. Rheumatology International, 2003, 23, 309-311.	1.5	19
150	Anterior Chest Wall Involvement in Early Stages of Spondyloarthritis: Advanced Diagnostic Tools. Journal of Rheumatology, 2012, 39, 1844-1849.	1.0	19
151	Joint and bone assessment in hand osteoarthritis. Clinical Rheumatology, 2014, 33, 11-19.	1.0	19
152	Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology. Clinical and Experimental Rheumatology, 2017, 35, 991-1010.	0.4	19
153	Rheumatic and autoimmune thyroid disorders: A causal or casual relationship?. Autoimmunity Reviews, 2015, 14, 57-63.	2.5	18
154	Self-reported flares are predictors of radiographic progression in rheumatoid arthritis patients in 28-joint disease activity score remission: a 24-month observational study. Arthritis Research and Therapy, 2016, 18, 89.	1.6	18
155	Autoantibody testing in patients with myositis: clinical accuracy of a multiparametric line immunoassay. Clinical and Experimental Rheumatology, 2017, 35, 176-177.	0.4	18
156	Clinical manifestations and outcome of polyarthralgia associated with chronic lymphocytic thyroiditis. Seminars in Arthritis and Rheumatism, 2002, 32, 51-55.	1.6	17
157	Autoinflammatory diseases: How to put the fire inside the body out?. Autoimmunity Reviews, 2012, 12, 1-4.	2.5	17
158	Detection of Calcium Crystals in Knee Osteoarthritis Synovial Fluid. Journal of Clinical Rheumatology, 2016, 22, 369-371.	0.5	17
159	Maternal autoantibody profiles at risk for autoimmune congenital heart block: a prospective study in high-risk patients. Lupus Science and Medicine, 2016, 3, e000129.	1.1	16
160	The prevalence of monosodium urate and calcium pyrophosphate crystals in synovial fluid from wrist and finger joints. Rheumatology International, 2016, 36, 443-446.	1.5	16
161	Spondyloarthritis: Matrix Metalloproteinasesas Biomarkers of Pathogenesis and Response to Tumor Necrosis Factor (TNF) Inhibitors. International Journal of Molecular Sciences, 2017, 18, 830.	1.8	16
162	Analysis of cartilage biomarkers in erosive and non-erosive osteoarthritis of the hands. Osteoarthritis and Cartilage, 2004, 12, 843-845.	0.6	15

#	Article	IF	CITATIONS
163	The clinical relevance of the IgM isotype of antiphospholipid antibodies in the vascular antiphospholipid syndrome. Thrombosis Research, 2015, 136, 883-886.	0.8	15
164	Impact of 24Âmonths of anti-TNF therapy versus methotrexate on body weight in patients with rheumatoid arthritis: a prospective observational study. Clinical Rheumatology, 2016, 35, 1615-1618.	1.0	15
165	Hyperuricemia, Cardiovascular Profile, and Comorbidity in Older Men and Women: The Pro.V.A. Study. Rejuvenation Research, 2017, 20, 42-49.	0.9	15
166	Late-Onset and Elderly Psoriatic Arthritis: Clinical Aspects and Management. Drugs and Aging, 2019, 36, 909-925.	1.3	15
167	Pathogenesis of Psoriatic Arthritis. Critical Reviews in Immunology, 2019, 39, 361-377.	1.0	15
168	Serum amyloid-A in Behçet's disease. Clinical Rheumatology, 2014, 33, 1165-1167.	1.0	14
169	Plasma-exchange as a "rescue therapy―for dermato/polymyositis in acute phase. Experience in three young patients. Transfusion and Apheresis Science, 2015, 53, 368-372.	0.5	14
170	SMAD4 loss enables EGF, $TGF\hat{l}^21$ and $S100A8/A9$ induced activation of critical pathways to invasion in human pancreatic adenocarcinoma cells. Oncotarget, 2016, 7, 69927-69944.	0.8	14
171	Predictors of Loss of Remission and Disease Flares in Patients with Axial Spondyloarthritis Receiving Antitumor Necrosis Factor Treatment: A Retrospective Study. Journal of Rheumatology, 2016, 43, 1541-1546.	1.0	14
172	Sarcopenic osteoarthritis: a new entity in geriatric medicine?. European Geriatric Medicine, 2018, 9, 141-148.	1.2	14
173	Lengthening the time intervals between doses of biological agents in psoriatic arthritis patients: A single-center retrospective study. International Journal of Immunopathology and Pharmacology, 2015, 28, 479-487.	1.0	13
174	Grade and location of power Doppler are predictive of damage progression in rheumatoid arthritis patients in clinical remission by anti-tumour necrosis factor 1±. Rheumatology, 2017, 56, 1320-1325.	0.9	13
175	Aging and osteoarthritis. Aging Clinical and Experimental Research, 2003, 15, 355-355.	1.4	12
176	Gastric dysmotility after liquid bolus ingestion in systemic sclerosis: an ultrasonographic study. Rheumatology International, 2012, 32, 1219-1223.	1.5	12
177	Change gout: how to deal with this "silently-developing killer―in everyday clinical practice. Current Medical Research and Opinion, 2018, 34, 1411-1417.	0.9	12
178	Periodontal Injection of Lipopolysaccharide Promotes Arthritis Development in Mice. Inflammation, 2019, 42, 1117-1128.	1.7	12
179	Diagnostic pratique desÂarthropathies microcristallines. Revue Du Rhumatisme (Edition Francaise), 2007, 74, 138-146.	0.0	11
180	Time to redefine erosive osteoarthritis. RMD Open, 2015, 1, e000105.	1.8	11

#	Article	IF	CITATIONS
181	ILâ€1ß and ILâ€8 are scavenged by the hexadecylamide derivative of hyaluronic acid: A new mechanism. Journal of Biomedical Materials Research - Part A, 2015, 103, 2823-2829.	2.1	11
182	Improvement of Function and Its Determinants in a Group of Axial Spondyloarthritis Patients Treated with TNF Inhibitors: A Real-Life Study. Rheumatology and Therapy, 2020, 7, 301-310.	1.1	11
183	Synovial Biomarkers in Psoriatic Arthritis. Journal of rheumatology Supplement, The, 2012, 89, 61-64.	2.2	10
184	Influenza vaccine with adjuvant on disease activity in psoriatic arthritis patients under anti-TNF- $\hat{l}\pm$ therapy. Clinical and Experimental Rheumatology, 2016, 34, 507-12.	0.4	10
185	Laboratory investigations in osteoarthritis. Aging Clinical and Experimental Research, 2003, 15, 373-379.	1.4	9
186	Laboratory Findings in Osteoarthritis. Seminars in Arthritis and Rheumatism, 2004, 34, 58-61.	1.6	9
187	Tinnitus and bilateral sensorineural hearing loss: Ankylosing spondylitis or a side-effect of sulphasalazine treatment?. Acta Oto-Laryngologica, 2005, 125, 671-673.	0.3	9
188	The social costs of digital ulcer management in sclerodema patients: An observational Italian pilot study. Joint Bone Spine, 2010, 77, 83-84.	0.8	9
189	The UltraSound-CLinical ARthritis Activity (US-CLARA) index: Properties of a new composite disease activity index for rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2018, 47, 619-629.	1.6	9
190	Mud-bath treatment of seronegative spondyloarthritis: experience at the Euganean Thermal Area. International Journal of Biometeorology, 2020, 64, 937-941.	1.3	9
191	Unusual Findings in Synovial Fluid Analysis: A Review. Annals of Clinical and Laboratory Science, 2017, 47, 253-259.	0.2	9
192	Chronic autoimmune thyroiditis and rheumatic manifestations. Joint Bone Spine, 2004, 71, 275-275.	0.8	8
193	Elderly psoriatic arthritis patients on TNF- \hat{l}_{\pm} blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate. Clinical Rheumatology, 2017, 36, 1797-1802.	1.0	8
194	Mediterranean Food Pattern in Rheumatoid Arthritis. Current Rheumatology Reviews, 2009, 5, 233-240.	0.4	8
195	"Are there any evidences for using the intra-articular TNF-α blockade in resistant arthritis?― Joint Bone Spine, 2011, 78, 331-334.	0.8	7
196	Bronchiolitis obliterans organizing pneumonia in patients with autoimmune rheumatic diseases. Immunologic Research, 2015, 61, 97-103.	1.3	7
197	The controversial relationship between osteoarthritis and osteoporosis: an update on hand subtypes. International Journal of Rheumatic Diseases, 2016, 19, 954-960.	0.9	7
198	Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study. Clinical and Experimental Rheumatology, 2016, 34, 68-75.	0.4	7

#	Article	IF	Citations
199	Response to 'Plasma proteins present in osteoarthritic synovial fluid can stimulate cytokine production via Toll-like receptor 4'. Arthritis Research and Therapy, 2012, 14, 405.	1.6	6
200	Blau syndrome and latent tubercular infection: an unresolved partnership. International Journal of Rheumatic Diseases, 2014, 17, 586-587.	0.9	6
201	A contribution to detection of anticardiolipin and anti- \hat{l}^2 2glycoprotein I antibodies: Comparison between a home-made ELISA and a fluorescence enzyme immunoassay. Clinica Chimica Acta, 2015, 446, 93-96.	0.5	6
202	Effect of pathogenic crystals on the production of pro- and anti-inflammatory cytokines by different leukocyte populations. Immunobiology, 2021, 226, 152042.	0.8	6
203	Cause-specific mortality in a large population-based cohort of patients with rheumatoid arthritis in Italy. Clinical and Experimental Rheumatology, 2018, 36, 636-642.	0.4	6
204	Multiple paradoxical adverse events in a patient affected with ankylosing spondylitis treated with TNF blockers. European Journal of Dermatology, 2011, 21, 263-264.	0.3	5
205	An unusual association between erosive hand osteoarthritis and morphea. Joint Bone Spine, 2011, 78, 532-533.	0.8	5
206	The potential role of bone scintigraphy in the detection of deep muscular fascia involvement and calcinosis cutis in anti-synthetase syndrome. International Journal of Rheumatic Diseases, 2013, 16, 495-496.	0.9	5
207	Costâ€Effectiveness Analysis of Two Rituximab Retreatment Regimens for Longstanding Rheumatoid Arthritis. Arthritis Care and Research, 2015, 67, 947-955.	1.5	5
208	Erosive osteoarthritis, psoriatic arthritis and pseudogout; a casual association?. Clinical Rheumatology, 2016, 35, 1885-1889.	1.0	5
209	A Pro-Inflammatory Signature Constitutively Activated in Monogenic Autoinflammatory Diseases. International Journal of Molecular Sciences, 2022, 23, 1828.	1.8	5
210	Normal values of laboratory tests in elderly onset psoriatic arthritis. Annals of the Rheumatic Diseases, 2000, 59, 239-239.	0.5	4
211	Systemic sclerosis in a patient with recent nasopharyngeal carcinoma: an unusual combination. Joint Bone Spine, 2003, 70, 396-397.	0.8	4
212	Rheumatic Manifestations Associated with Inflammatory Bowel Diseases. Current Rheumatology Reviews, 2007, 3, 47-56.	0.4	4
213	Efficacy and Safety of Certolizumab Pegol in Rheumatoid Arthritis: Meeting Rheumatologists' Requirements in Routine Clinical Practice. BioDrugs, 2014, 28, 25-37.	2,2	4
214	Why are rheumatologists still reluctant to perform joint-fluid analysis?. Joint Bone Spine, 2015, 82, 139-140.	0.8	4
215	Long-term improvement in activities of daily living in women with systemic sclerosis attending occupational therapy. British Journal of Occupational Therapy, 2017, 80, 417-422.	0.5	4
216	Clinical Overlapping in Autoinflammatory Diseases: The Role of Gene Duplication. Frontiers in Immunology, 2017, 8, 392.	2.2	4

#	Article	IF	CITATIONS
217	Fibromyalgie chez les patients italiens atteint d'un syndrome de Gougerot-Sj¶gren primitif. Revue Du Rhumatisme (Edition Francaise), 2002, 69, 56-63.	0.0	3
218	International position paper on febuxostat. Clinical Rheumatology, 2010, 29, 835.	1.0	3
219	Health-related quality of life, illness perception, coping strategies and the distribution of dependency in autoinflammatory diseases. Clinical and Experimental Rheumatology, 2019, 37 Suppl 121, 156-157.	0.4	3
220	Acute Calcium Pyrophosphate Crystal Arthritis of the Wrist Elicited by Anti-COVID-19 Vaccination After Carpal Tunnel Release. American Journal of Case Reports, 2022, 23, e934833.	0.3	3
221	Thyro $ ilde{A}^{-}$ dite chronique auto-immune et manifestations rhumatologiques. Revue Du Rhumatisme (Edition) Tj ETQq1	J.8.7843	1 ₂ 4 rgBT /
222	Erosive hand osteoarthritis and systemic sclerosis: A casual association?. Joint Bone Spine, 2012, 79, 507-509.	0.8	2
223	Editorial: IL-1 Inhibition. Frontiers in Pharmacology, 2019, 10, 87.	1.6	2
224	The Mediterranean Diet and Arthritis. , 2015, , 461-472.		1
225	107.â€fFULLY INTEGRATED 18F-FDG PET/MR IN LARGE VESSEL VASCULITIS. Rheumatology, 2019, 58, .	0.9	1
226	Sclérodermie systémique chez un patient ayant un carcinome nasopharyngien récentÂ: une association inhabituelle. Revue Du Rhumatisme (Edition Francaise), 2003, 70, 779-780.	0.0	0
227	Thyro�dite chronique auto-immune et manifestations rhumatologiques. Clinical Cornerstone, 2004, 2003, 555-555.	1.0	O
228	Traitement parÂboue etÂeau thermales dansÂlaÂspondylarthrite associée ÃÂuneÂentérocolopathie inflammatoire: essai clinique pilote randomisé. Revue Du Rhumatisme (Edition Francaise), 2007, 74, 833-837.	0.0	0
229	Syndrome des antisynthétases avec polyarthrite réfractaire et fièvre, traité avec succès avec l'anakinra, antagoniste du récepteur de l'IL-1. Revue Du Rhumatisme (Edition Francaise), 2008, 75, 504-505.	0.0	O
230	Coûts socioéconomiques du traitement des ulcères digitaux chez les patients atteints de sclérodermie systémiqueÂ: étude pilote d'observation en Italie. Revue Du Rhumatisme (Edition Francaise), 2010, 77, 105-106.	0.0	O
231	An introduction to common and uncommon clinical or metabolic diseases with rheumatic phenotypes. Best Practice and Research in Clinical Rheumatology, 2011, 25, 625-626.	1.4	O
232	Arthrose digitale érosive et sclérodermieÂ: une association occasionnelleÂ?. Revue Du Rhumatisme (Edition Francaise), 2012, 79, 564-566.	0.0	O
233	Blocage intra-articulaire du TNF dans la spondylarthrite périphériqueÂ: sa pertinence par rapport aux scores clinique, à l'imagerie quantitative, et aux biomarqueurs dans le liquide synovial et le tissu synovial. Revue Du Rhumatisme (Edition Francaise), 2013, 80, 149-156.	0.0	O
234	Efficacité thérapeutique du rituximab chez un jeune patient atteint d'une maladie systémique associéaux IgG4Âavec sclérite réfractaire. Revue Du Rhumatisme (Edition Francaise), 2014, 81, 264-265.	96.o	0

#	Article	IF	CITATIONS
235	Progression de l'athérosclérose chez les patients ayant un rhumatisme psoriasique malgré un traitement par anti-TNF-alphaÂ: étude prospective observationnelle de 2Âans. Revue Du Rhumatisme (Edition Francaise), 2014, 81, 395-399.	0.0	O
236	FRI0064â€INCREASE OF RHEUMATOID ARTHRITIS AS A CONTRIBUTORY CAUSE OF DEATH IN THE ELDERLY. A NATIONWIDE STUDY IN ITALY, 2003–2015. , 2019, , .		0
237	THU0123â€FEMALES UNDERGO MORE TREATMENT CHANGES COMPARED TO MALES: ANALYSIS OF GENDER DIFFERENCES IN RHEUMATOID ARTHRITIS PATIENTS. , 2019, , .		0
238	The Mediterranean diet and arthritis. , 2020, , 393-407.		0
239	Atypical erythema nodosum in atypical tuberculosis presentation. BMJ Case Reports, 2009, 2009, bcr0920080944-bcr0920080944.	0.2	O
240	NKG2D ligands in inflammatory joint diseases: analysis in human samples and mouse models. Clinical and Experimental Rheumatology, 2021, 39, 982-987.	0.4	0
241	The forward-looking advertising. Description of a gouty heart in a 1919 advertisement. Joint Bone Spine, 2022, 89, 105398.	0.8	O